

Daniel Richardson, Shievon Smith and Michelle Greenwood

Uro-Oncology Clinical Nurse Specialists at St Bartholomew's Hospital, Bart's Health NHS Trust



ABSTRACT

Previously we explored patient long-term toxicity and safety to deliver Carboplatin AUC10 for metastatic seminoma. For 40 years the debate has run, could testicular cancer patients be cured with single agent Carboplatin AUC10 x 3 cycles.

An updated series confirmed similar cure rates to combination BEP chemotherapy with extended follow up. The CarPET trial and further data from 216 patients confirmed overall survival was comparable to standard of care BEP chemotherapy with patients reporting lower toxicities: fatigue 2%, vomiting 2%, febrile neutropenia 1%^{1 2}.

In light of the above, we wanted to compliment this trial and explore patients experiences of Carboplatin AUC10 compared to three cycles of BEP chemotherapy at St Bartholomew's Hospital.

METHODS



In January 2023, a questionnaire about experiences on BEP or Carboplatin AUC10 was added onto our St Bartholomew's Testicular Cancer support group closed Facebook page which has over 294 individuals, and a further 320 patients were sent the questionnaire on email and a paper questionnaires were given out in clinic.

RESULTS

A total of 45 patients completed the questionnaire, 18 of which were treated with Carboplatin AUC10 and 27 patients were treated with BEP. We found the following results:

- 16 patients reported being pleased that they had AUC10 following discussions with the group and 2 patients reported being unable to compare.
- A total of 27 patients reported being able to continue to work throughout chemotherapy.
- 4 patients required a blood transfusions in the AUC10 group.

RESULTS CONTINUED

- 14 patients on BEP reported hearing loss.
- 27 patients on BEP reported hair loss.
- 21 patients on BEP reported peripheral neuropathy.
- A further 18 patients on BEP reported extreme fatigue, nausea and vomiting, skin problems and loss of concentration.

CONCLUSION

Carboplatin AUC10 has equivalent outcomes compared with BEP to cure metastatic seminoma patients. However, the side effect profile reported by patient's shows huge improvements in quality of life during and after chemotherapy.

Patients have also reported outside of the questionnaire that they found reassurance that Carboplatin AUC10 is a one hour infusion every 3 weeks, as opposed to the typical 2 night inpatient admission for BEP, followed by Bleomycin at day 10 and day 15.

Although the side effect profile is better with Carboplatin, long-term effects of chemotherapy should still be monitored carefully.

REFERENCES

- 1 Shamash et al. (2016) Carboplatin AUC10 in metastatic seminoma: Role of early PET scanning to reduce the amount of treatment while maintain outcome – A phase 2 study (CarPET). Journal of Clinical Oncology 34 (15_suppl):4545-4545. Available online at: https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.4545
- 2 Alifrangis et al. (2019) Carboplatin AUC10 monotherapy for metastatic seminoma – an updated multicentre review of outcomes in 216 patients. European Urology Supplements. 18 (4):18